Function of the  T-box factor TBX-2 depends on SUMOylation by unknown
1 3
DOI 10.1007/s00018-013-1336-y Cellular and Molecular Life Sciences
Cell. Mol. Life Sci. (2013) 70:4157–4168
ReSeaRCh aRtICLe
Function of the C. elegans T-box factor TBX-2 depends  
on SUMOylation
Paul Huber · Tanya Crum · Lynn M. Clary · 
Tom Ronan · Adelaide V. Packard · Peter G. Okkema 
Received: 7 February 2013 / Revised: 19 March 2013 / accepted: 2 april 2013 / Published online: 18 april 2013 
© the author(s) 2013. this article is published with open access at Springerlink.com
of a 5xGal4:tk:luciferase construct. however, this activ-
ity does not require SUMOylation, indicating SUMO is 
not generally required for tBX-2 repressor activity. In 
C. elegans, reducing SUMOylation enhances the pheno-
type of a temperature-sensitive tbx-2 mutant and results in 
ectopic expression of a gene normally repressed by tBX-2, 
demonstrating that SUMOylation is important for tBX-2 
function in vivo. Finally, we show mammalian orthologs 
of tBX-2, tbx2, and tbx3, can also be SUMOylated, sug-
gesting SUMOylation may be a conserved mechanism con-
trolling t-box factor activity.
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Genetic enhancer
Introduction
t-box proteins are a family of transcription factors found 
in all multicellular animals where they play important roles 
in the development of a variety of tissues [1, 2]. the defin-
ing feature of this family is the conserved t-box DNa-
binding domain, and t-box factors are grouped into distinct 
sub-families based on sequence conservation within this 
domain. In many cases, the level of t-box factor activity 
is crucial to normal function. For example, reduced expres-
sion of the human tbx2 sub-family genes TBX3, TBX4, and 
TBX5 resulting from loss of one functional allele results 
in ulnar-mammary syndrome, small patella syndrome, 
and holt-Oram syndrome, respectively [3–7]. In contrast, 
over-expression of the tbx2-subfamily genes TBX2 and 
TBX3 is found in a number of human cancers [8]. Despite 
their developmental and clinical importance, relatively 
little is known about the mechanism by which t-box 
factors function.
Abstract t-box transcription factors are critical devel-
opmental regulators in all multi-cellular organisms, and 
altered t-box factor activity is associated with a variety of 
human congenital diseases and cancers. Despite the bio-
logical significance of t-box factors, their mechanism of 
action is not well understood. here we examine whether 
SUMOylation affects the function of the C. elegans tbx2 
sub-family t-box factor tBX-2. We have previously shown 
that tBX-2 interacts with the e2 SUMO-conjugating 
enzyme UBC-9, and that loss of tBX-2 or UBC-9 pro-
duces identical defects in aBa-derived pharyngeal muscle 
development. We now show that tBX-2 is SUMOylated 
in mammalian cell assays, and that both UBC-9 interac-
tion and SUMOylation depends on two SUMO consensus 
sites located in the t-box DNa binding domain and near 
the tBX-2 C-terminus, respectively. In co-transfection 
assays, a tBX-2:GaL4 fusion protein represses expression 
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We are interested in the role that SUMOylation plays 
in t-box factor activity. SUMOylation is the covalent 
and reversible post-translational attachment of the small 
ubiquitin-like modifier peptide (SUMO) to specific lysine 
residues in target proteins [9, 10], and it has been impli-
cated in diverse processes, including modifying function, 
nuclear localization, and sub-nuclear localization of tran-
scriptional regulators [11]. SUMOylation of transcription 
factors is typically associated with repression [12], but it 
has also been implicated in transcriptional activation by 
some factors [13, 14]. the SUMO conjugation pathway is 
analogous to the ubiquitination pathway and involves an 
e1-activating enzyme (aos1/Uba2) and an e2 conjugating 
enzyme (Ubc9) sufficient for specific SUMO attachment in 
vitro [15, 16]. In addition, a variety of e3 ligases have been 
identified that promote SUMO transfer from e2 to specific 
substrates in vivo. Ubc9 recognizes the ΨKX(D/e) SUMO 
consensus site (where Ψ is a large hydrophobic amino 
acid and K is the residue attached to SUMO) [17, 18], 
and many SUMOylation substrates have been identified 
by their interaction with Ubc9 in yeast two-hybrid screens 
[19]. SUMOylation also occurs at non-consensus sites, and 
non-covalent SUMO/substrate or e3 ligase/substrate inter-
actions are involved in directing SUMOylation at these 
sites [9].
We hypothesize that function of the C. elegans t-box 
factor tBX-2 depends on SUMOylation [20]. tBX-2 is 
the sole C. elegans member of the tbx2 subfamily and is 
necessary for formation of anterior pharyngeal muscles. 
In yeast two-hybrid assays, tBX-2 interacts with the e2 
SUMO conjugating enzyme UBC-9, and loss of UBC-9 
produces pharyngeal phenotypes identical to those result-
ing from tbx-2 loss-of-function. In addition, sub-nuclear 
localization of a tBX-2::GFP fusion protein is altered 
when SUMOylation is reduced.
here, we ask if tBX-2 is SUMOylated and whether 
SUMOylation affects tBX-2 activity in vivo. We first 
used the two-hybrid assay to map interaction sites between 
tBX-2 and UBC-9 and found two SUMO consensus sites 
in tBX-2 that mediate interaction with UBC-9. One of 
these sites is located near the tBX-2 C-terminus, while 
the other is located in a highly conserved region of the 
t-box DNa binding domain. We next showed that tBX-2 
is SUMOylated in mammalian cell assays, and that tBX-2 
SUMOylation depends on both of these UBC-9 interac-
tion sites. We then examined tBX-2 transcriptional activity 
and found that in mammalian cells a tBX-2-GaL4 DNa-
binding domain (GaL4-DBD) fusion protein represses 
expression of a GaL4-responsive reporter, but surprisingly 
this repression did not require SUMOylation. to determine 
whether SUMOylation is important for tBX-2 activity in 
vivo, we asked if tbx-2 and ubc-9 interact genetically. We 
found that reduction of SUMOylation enhances the effect 
of a tbx-2 hypomorphic mutant on embryonic viability 
and pharyngeal muscle development, and that repression 
of a downstream target of tBX-2 depends on SUMOyla-
tion. Finally, we examined SUMOylation of two mam-
malian orthologs of tBX-2 and found that human tBX2 
and mouse tbx3 can also be SUMOylated. We suggest 
SUMOylation is a common mechanism regulating activity 
of t-box transcription factors.
Materials and methods
Nematode handling, transformation, and strains
C. elegans were grown under standard conditions [21]. 
Germ line transformation was performed using standard 
techniques with pRF4 containing rol-6(su1006) as a domi-
nant marker for transformation [22]. the following strains 
were used in these studies: OK0660 tbx-2(bx59) obtained 
by outcrossing from eM207 tbx-2(bx59); him-5(e1490); 
OK0666 cuEx553[D2096.6::gfp]; OK0692 tbx-2(bx59); 
cuEx553[D2096.6::gfp]; OK0741 tbx-2(ok529)/dpy-17(e164) 
unc-32(e189); cuEx553[D2096.6::gfp].
Genotyping tbx-2(bx59) mutants
tbx-2(bx59) is a G→a substitution located at position 
24,597 of the cosmid F21h11 (accession FO081200) 
(K. Chow, pers. comm.) and disrupts a BstCI restriction 
enzyme site. animals were genotyped by single worm PCR 
[23] using primers PO931 [aGtttGaCaCCGattttCt 
CG] and PO932 [GtGatGatGGatCttGttCCG] fol-
lowed by digestion with BstCI and gel electrophoresis.
General methods for nucleic acid manipulations  
and plasmid construction
Standard methods were used to manipulate plasmid DNas 
and oligonucleotides [24], and all plasmid sequences are 
available from the authors. For yeast two-hybrid assays, 
the LKIe and VKKe SUMOylation sites were separately 
mutated using the Stratagene QuikChange II Kit in the 
tbx-2 bait plasmid pOK187.01 containing the full-length 
tbx-2 orf [20] to generate pOK222.01 and pOK222.06, 
respectively. the LKIe/VKKe→aaaa double mutant 
was constructed by ligation of fragments pOK222.01 and 
pOK226.06 to create the plasmid pOK225.02. Plasmids 
for expressing tBX-2 (pOK241.05), tBX-2LKIe→aaaa 
(pOK241.10), tBX-2VKKe→aaaa (pOK241.13), and 
tBX-2LKIe/VKKe→aaaa (pOK241.17) were constructed by 
inserting the PCR amplified tbx-2 orf from the two-hybrid 
vectors into pCDNa3.1 using tOPO cloning (Invitro-
gen). Plasmids for expressing tBX-2K231R (pOK263.01), 
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tBX-2K400R (pOK244.18), and the tBX-22KR double 
mutant (pOK261.03) were made by site-directed mutagen-
esis of pOK241.05 using the Stratagene QuikChange II 
Kit. the plasmid encoding ha::SUMO-1 (pcDNa3 ha 
SUMO-1, pOK251.01) was a gift from Jorge a. Iñiguez-
Lluhí (University of Michigan), and it was mutated using 
the Stratagene QuikChange II Kit to encode ha::SUMO-
1(ΔGG) (pOK263.05). cDNa clones for human tBX2 
(IMaGe:6339405) and mouse tbx3 (IMaGe:30547736) 
were purchased from Open Biosystems and inserted into 
pCDNa3.1 using tOPO cloning to make pOK246.01 and 
pOK245.01.
Plasmids for expressing tBX-2:GaL4 (pOK253.01) and 
tBX-2LKIe/VKKe→aaaa:GaL4 (pOK253.04) for co-trans-
fection assays were made by cloning the amplified tbx-2 
orf from pOK241.05 and 241.17, respectively, into pcDNa 
ha:GaL4(1-100) (provided by Jorge a. Iñiguez-Lluhí, Uni-
versity of Michigan). For mock transfections, the ha:GaL4 
fragment was removed from pcDNa ha:GaL4(1–100) 
(pOK293.03). the 5xGaL4:tk:luc reporter was a gift 
from elizaveta Benevolenskaya, University of Illinois at 
Chicago.
Yeast two-hybrid assays
Yeast 2-hybrid assays were carried out in L40 yeast con-
taining hIS3 and lacZ reporters regulated by Lexa binding 
sites with the ubc-9 prey plasmid pOK193.11 in the paCt 
vector and tbx-2 bait plasmids pOK187.01 (wild-type 
tbx-2), pOK222.01 (tbx-2LKIe→aaaa), pOK222.06 (tbx-
2VKKe→aaaa), or pOK225.02 (tbx-2LKIe/VKKe→aaaa) in the 
pLexa-NLS vector as previously described [20]. ß-galac-
tosidase expression in yeast was quantified in at least three 
assays as previously described [25].
RNai analyses
Feeding RNai was performed as previously described 
[26] using plasmids obtained from Geneservice containing 
genomic fragments of ubc-9 or smo-1 cloned into L4440 
[27]. to assess enhancement of the tbx-2(bx59) mutant 
phenotype, N2 or OK0660 [tbx-2(bx59)] L4 hermaphro-
dites raised at 16 °C were transferred to plates seeded with 
RNai feeding E. coli or OP50 and incubated at 25 °C for 
24 h. these animals were transferred to fresh feeding plates 
at 25 °C and allowed to lay eggs for 4 h. Progeny embryos 
were transferred to fresh feeding plates and counted. Larvae 
and terminally arrested embryos were counted 24 h later to 
assay embryonic lethality, or examined by DIC microscopy 
after hatching to assess the pharyngeal phenotype.
to examine D2096.6::gfp expression, OK0666 [cuEx553] 
L4 hermaphrodites were transferred to plates seeded 
with ubc-9 RNai feeding E. coli or OP50 and grown 20 h 
at 20 °C. these animals were transferred to fresh feed-
ing plates, and GFP expression was examined in progeny 
embryos and larvae.
SUMOylation and co-transfection assays
COS-1 cells were maintained in D-MeM with 10 % FBS, 
10 mM hePeS, and 1× antibiotic–antimycotic (Invitro-
gen). For SUMOylation assays, ~2 × 106 cells were seeded 
into 10-cm plates 24 h prior to transfection. Plates were 
transfected with plasmids expressing wild-type or mutant 
tBX-2 (10 μg), ha-SUMO-1 or ha-SUMO-1(ΔGG) 
(10 μg), and peGFP-N3 (4 μg; Clontech) using Lipo-
fectamine 2000 in OPtI-MeM following the manufactur-
er’s instructions (Invitrogen). after 48 h, COS-1 cells were 
harvested in PBS, lysed in 0.75 ml lysis buffer [8 M urea, 
0.5 M NaCl, 45 mM Na2hPO4, 5 mM Nah2PO4,10 mM 
imidazole, 10 mM NeM (ph 8.0)], sonicated, and incu-
bated with 50 μl Ni–Nta magnetic beads (Qiagen). Beads 
were washed twice with 1 ml wash [8 M urea, 0.4 M NaCl, 
17.6 mM Na2hPO4, 32.4 mM Nah2PO4, 10 mM imidazole, 
10 mM NeM (ph 6.75)] on a MagnaRack (Invitrogen). 
Protein was eluted in 50 μl (250 mM imidazole, 5 % SDS, 
0.15 M tris ph6.7, 30 % glycerol, 0.72 M ßMe), resolved 
by SDS-PaGe, and blotted. Proteins were detected using 
anti-V5 (Invitrogen) or anti-ha (Covance), hRP-conju-
gated secondary antibody (Goat anti-mouse, Millipore), 
and eCL Plus (Ge healthcare) detection reagent. Chemi-
luminescence was recorded using eCL hyperfilm (Ge 
healthcare) or recorded and quantified using a StORM 
860 Molecular Imager and ImageQuant software (Molecu-
lar Dynamics).
For co-transfection assays, 2 × 105 COS-1 cells were 
seeded to wells of a 24-well plate 24 h prior to transfec-
tion. Wells were transfected with plasmids expressing 
tBX-2 (25–500 ng), 5xGaL4:tk:luc (280 ng), and CMV 
ßgal (20 ng) using Lipofectamine 2000 in OPtI-MeM fol-
lowing the manufacturer’s instructions (Invitrogen) and 
harvested. Luciferase and ß-gal were measured in triplicate 
samples using Steady Glo Luciferase system (Promega) 
and a Clarity Luminescence Micro-plate reader (BIO-
teK), and ßgal activity was measured with a Genesys 10 
UV spectrophotometer (thermo-Fisher) [28].
Microarray and data analysis
Mixed stage populations of N2 and OK0660 [tbx-2(bx59)] 
animals grown at 25 °C were treated with bleach/sodium 
hypochlorite to isolate embryos [21]. aliquots of embryos 
were examined to verify comparable age distributions, and 
RNa was isolated using tRIzol (Invitrogen) and further 
purified using RNeasy Kit (Qiagen) following manufactur-
ers’ protocols.
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total RNa from two independent populations of N2 
embryos and three independent tbx-2(bx59) embryos were 
labeled and hybridized to affymetrix C. elegans Genome 
GeneChips by the UIC Core Genomic Facility (CGF). the 
microarray data was analyzed using the R statistical pro-
gramming language, using the Bioconductor suite of tools 
[29], and the affy package. Normalization to correct for 
chip-to-chip variation was done using the Robust Multiar-
ray averaging (RMa) method of microarray normalization 
[30]. Microarray results were pre-filtered using the genefil-
ter function (25 % of the probes have a measured intensity 
of at least 100 on the original scale and the coefficient of 
variation is between 0.7 and 10 on the original scale) [31]. 
the limma package [32] was used to calculate differen-
tial expression using the limma linear model fit, eBayes 
smoothing of standard errors, and Benjamini-hochberg 
(Bh) multiple test correction with a false discovery rate of 
5 % [33]. Probes were matched to genes using the affy-
metrix-to-WormBase ID table for WS210 (http//:www.wo
rmbase.org). Probes mapping to more than one gene were 
discarded. When one or more probes mapping to a gene 
were differentially expressed, that gene was considered to 
be differentially expressed. One GeneChip hybridized with 
tbx-2(bx59) RNa exhibited high variation in the spiked in 
control probes (tBXa) compared to the other samples, and 
data from this chip was not included in our analysis.
Microscopy
Worms were visualized using a Zeiss axioskop microscope 
equipped for DIC and fluorescence microscopy, and images 
were captured using an axiocam MRm camera and axio-
Vision software.
Results
tBX-2 interacts with UBC-9 via two SUMO consensus 
sites
We previously showed using yeast two-hybrid assays that 
tBX-2 specifically interacts with the e2 SUMO-conju-
gating enzyme UBC-9 [20], and we used this assay to 
identify sites in tBX-2 mediating this interaction. tBX-2 
contains several sites matching the SUMO consensus site 
ΨKX(D/e) (Supplementary table 1) [17, 18]. the two 
highest-scoring matches to this consensus are an LK231Ie 
sequence located near the C-terminus of the t-box DNa 
binding domain and a VK400Ke sequence located near the 
tBX-2 C-terminus (Fig. 1a). LKIe is located in a con-
served region of the t-box, and a SUMO consensus site is 
found at this position in many t-box factors, including all 
members of the tbx2 sub-family [34]. VKKe is located in 
a region that is not highly conserved among t-box factors, 
although high scoring SUMO consensus sites are found 
near the C-terminus of tBX-2 proteins from C. elegans, 
C. briggsae, and C. remanei, suggesting this site may be 
functionally conserved (Fig. 1b). We mutated each of these 
two sites in C. elegans tBX-2 to all alanines either in sin-
gle mutants (LKIe→aaaa or VKKe→aaaa) or in a 
double mutant (LKIe/VKKe→aaaa) and tested whether 
these mutants affected the ability of a tBX-2 bait to inter-
act with UBC-9 prey. Interactions were scored in plate 
assays for histidine prototrophy and ß-galactosidase (ß-gal) 
expression, and the level of interaction was quantified by 
measuring ß-gal activity.
We found that UBC-9 interaction with tBX-2 was 
affected by mutations affecting both the LKIe and VKKe 
sites. UBC-9 interacted with both the tBX-2LKIe→aaaa 
and tBX-2VKKe→aaaa single mutants in plate assays, but 
this interaction was reduced to 63 and 22 % of the lev-
els observed for wild-type tBX-2, respectively (Fig. 1b). 
Fig. 1  tBX-2 interacts with UBC-9. a Schematic diagram of the 
tBX-2 protein (accession CCD69847) indicating the location 
of the t-box DNa binding domain (black) and the positions of the 
LK231Ie and VK400Ke SUMO consensus sites. b t-Coffee alignment 
of the C-terminus of tBX-2 proteins from C. elegans (CetBX-2), 
C. briggsae (CbtBX-2; WormBase ID CBP05056), and C. remanei 
(CrtBX-2; WormBase ID RP21057) [62]. high-scoring SUMO con-
sensus sites are indicated in grey, and identical residues are marked 
with asterisks. c Quantification of ß-galactosidase activity in yeast 
expressing the indicated tBX-2 protein or the empty pLexa as bait 
and UBC-9 prey in replicate samples from three independent experi-
ments (n = 7). Differences between mutants and wild-type tBX-2 or 
different mutants (bracket) are statistically significant at *p < 0.05 or 
**p < 0.005. Error bars indicate the standard error of the mean
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In comparison, UBC-9 failed to interact with the tBX-
2LKIe/VKKe→aaaa double mutant in plate assays, and the 
ß-gal activity was close to that obtained using an empty 
bait plasmid (Fig. 1b, Supplementary Figure 1). as a con-
trol, we found that wild-type and all of the mutant tBX-2 
proteins retained the ability to interact with an unrelated 
protein UNC-37 in yeast two-hybrid assays, indicating the 
mutant proteins were expressed (Supplementary Figure 1). 
thus, both the LKIe and VKKe sites can interact with 
UBC-9. Because mutating both of these sites reduces inter-
action to near background, we believe they are the primary 
sites in tBX-2 that mediate this interaction. We have not 
tested other potential tBX-2 SUMOylation sites for inter-
action with UBC-9 in two-hybrid assays.
tBX-2 can be SUMOylated in mammalian cell assays
to determine if tBX-2 can be SUMOylated, we co-expressed 
full-length tBX-2 and human SUMO-1 in COS-1 cells. 
tBX-2 was fused to poly-histidine and pulled down using 
Ni2+-beads under denaturing conditions, while tBX-2 
and SUMO-1 were tagged with V5 and ha epitope tags, 
respectively, for detection on Western blots. a SUMO-
1ΔGG mutant lacking the C-terminal Gly–Gly motif 
required for conjugation to target lysine residues was used 
as a control to demonstrate SUMO conjugation.
When co-expressed with SUMO-1, wild-type tBX-2 
formed several more slowly migrating bands detectable 
with both anti-ha and anti-V5 (Fig. 2a). these bands 
likely represent mono- and multi-SUMOylated tBX-
2, although proteins SUMOylated at different sites can 
also migrate at different positions due to the branched 
nature of the SUMOylated protein [35]. In comparison, no 
SUMOylated tBX-2 was detected when co-expressed with 
SUMO-1ΔGG. as for many SUMOylated proteins, we 
found only a fraction of tBX-2 (~10 %) is SUMOylated 
in these assays. Similar results were obtained when tBX-2 
was co-expressed with human SUMO-2 or SUMO-3 (Sup-
plementary Figure 2).
We next asked how mutations in the UBC-9 interac-
tion sites affected tBX-2 SUMOylation. SUMOylation of 
tBX-2LKIe→aaaa and tBX-2VKKe→aaaa were reduced 
to approximately 30 and 70 % of the level of wild-type 
tBX-2, respectively, while SUMOylation of the tBX-
2LKIe/VKKe→aaaa double mutant was further reduced to a 
level comparable to background (Fig. 2a, lanes 2 and 9). 
these results indicate that tBX-2 can be SUMOylated, and 
that the LKIe and VKKe sites for UBC-9 interaction are 
required for tBX-2 SUMOylation.
We next mutated the SUMO-conjugated lysine residues 
in the LKIe and VKKe sites to arginine, which is a con-
servative substitution that cannot be conjugated to SUMO, 
and we examined SUMOylation in COS-1 cells (Fig. 2b). 
the tBX-2K231R mutant affecting LKIe exhibited reduc-
tion of the more slowly migrating SUMOylated products, 
but these products were not eliminated, while the fast-
est migrating band appeared unaffected. In comparison, 
overall SUMOylation of the tBX-2K400R mutant affecting 
VKKe was strongly reduced, and the fast migrating form 
of SUMOylated tBX-2 was nearly completely eliminated. 
SUMOylation of the tBX-22KR double mutant containing 
K231R and K400R was similar to that of the tBX-2K400R 
single mutant, but this mutant was still SUMOylated 
above background levels (compare Fig. 2b, lanes 2 and 9). 
Because both of these conservative mutations affect the 
pattern of tBX-2 SUMOylation, we believe lysine residues 
in both the LKIe and VKKe SUMO consensus sites are 
SUMOylated.
Fig. 2  SUMOylation of tBX-2 is mediated via two SUMO consen-
sus sites. Western blots of Ni–Nta pulled-down wild-type and mutant 
tBX-2/V5/hIS probed to detect tBX-2 (bottom) or SUMO-1 (top). 
Combinations of proteins (grey boxes) were expressed in COS-1 cells. 
a Wild-type tBX-2 and mutants with SUMOylation sites converted 
to all alanines. b Wild-type tBX-2 and mutants with SUMO accep-
tor lysines converted to arginines. the position of the fastest migrat-
ing SUMOylated form of tBX-2 is indicated (bar and circle) and the 
position of molecular weight markers are indicated in kDa (bars). Sig-
nal in the lower panel in a was detected using a StORM Molecular 
Imager and clearly demonstrates more slowly migrating tBX-2 bands 
when co-transfected with SUMO-1. tBX-2/V5/hIS is ~52 kDa, and 
ha-SUMO-1 is ~13 kDa. the fastest migrating SUMOylated form 
migrates somewhat slower than predicted by its molecular weight, 
which is a common feature of SUMOylated proteins
4162 P. Huber et al.
1 3
tBX-2 is a transcriptional repressor in mammalian cells
C. elegans tBX-2 is most closely related to the mamma-
lian t-box repressors tbx2 and tbx3 [20]. We wanted to 
ask if tBX-2 functions similarly to repress transcription 
and, if so, whether this activity depends on SUMOylation. 
Because mutations affecting the LKIe SUMOylation would 
likely affect DNa binding, we asked if tBX-2 fused to the 
heterologous GaL4 DNa binding domain (tBX-2:GaL4) 
could repress expression of the 5xGaL4:tk:luc reporter. 
this reporter contains five copies of the GaL4 binding site 
upstream of thymidine kinase promoter:luciferase reporter, 
and tBX-2:GaL4 repressed expression of this reporter up 
to fivefold (Fig. 3). SUMOylation is most often associated 
with transcriptional repression, and we expected that muta-
tion of the LKIe and VKKe SUMO sites would reduce 
this repressor activity. however, we found that the tBX-
2LKIe/VKKe→aaaa double mutant repressed 5xGaL4:tk:luc 
similarly to wild-type tBX-2. Co-expressing SUMO-1 did 
not affect repression of 5xGaL4:tk:luc with either wild-
type or mutant tBX-2 (Supplementary Figure 3). thus, 
SUMOylation is not required for tBX-2:GaL4 repressor 
activity in COS-1 cells.
tBX-2 function is SUMO-dependent in C. elegans
mab-22(bx59) is a temperature-sensitive mutant that exhib-
its defects in male tail ray formation and partially penetrant 
larval lethality. bx59 has recently been identified as a mis-
sense mutation in tbx-2 (King Chow, pers. comm.), and 
we subsequently refer to this mutation as tbx-2(bx59). We 
examined the viability and pharyngeal morphology of tbx-
2(bx59) mutants produced from hermaphrodites shifted to 
the non-permissive temperature (25 °C) at the L4 stage. 
Forty-four % of these animals arrested at the L1 stage 
(n = 64) with variable pharyngeal abnormalities (Fig. 4a–c). 
these phenotypes are similar to those observed in tbx-
2(RNAi) animals and are not as severe as those observed 
in tbx-2 null mutants [20, 36], and we conclude that tbx-
2(bx59) is a hypomorphic allele.
We hypothesize that tBX-2 function depends on 
SUMOylation. to test this hypothesis, we asked if inhib-
iting SUMOylation by reducing UBC-9 or the SUMO 
Fig. 3  Dose-dependent transcriptional repression by tBX-2:GaL4. 
Relative luciferase activity in experiments co-transfecting increas-
ing amounts of wild-type and mutant tBX-2:GaL4 with the 
5xGaL4:tk:luc reporter. Data shown is the average of three assays 
and is representative of multiple independent experiments. Error bars 
indicate standard deviation. Statistically significant differences from 
control transfections are marked (*p < 0.05)
Fig. 4  Pharyngeal defects in tbx-2(bx59) mutant are enhanced by 
reduced SUMOylation DIC micrographs of the pharynx of L1 larvae 
of the indicated genotypes raised at the non-permissive temperature 
(25 °C). a Wild-type N2. b tbx-2(bx59) exhibiting a mild pharyngeal 
defect. c tbx-2(bx59) exhibiting a more severe pharyngeal defect. tbx-
2(bx59); ubc-9(RNAi) (d) and tbx-2(bx59); smo-1(RNAi) (e) L1 larvae 
exhibiting very severe defects resembling those of tbx-2 null mutants. 
Arrowheads mark the extent of pharyngeal tissue. anterior is left. the 
frequency of these phenotypes is indicated in table 1
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protein SMO-1 by RNai could enhance the phenotype of 
tbx-2(bx59) mutants. Using the RNai-feeding method, 
we found that ubc-9(RNAi) produced a relatively low fre-
quency of embryonic arrest in a wild-type background 
(table 1) [26]. In comparison, tbx-2(bx59); ubc-9(RNAi) 
double mutants exhibited a synergistic increase in the 
frequency of arrested embryos (table 1). tbx-2(bx59); 
smo-1(RNAi) double mutants also exhibited an increased 
frequency of embryonic lethality compared to each sin-
gle mutant; however, the smo-1(RNAi) lethality alone was 
higher making it difficult to determine if the double mutant 
lethality was more than additive (table 1).
Many of the tbx-2(bx59) mutants that hatch grow to 
adulthood, but nearly all of the tbx-2(bx59); ubc-9(RNAi) 
and tbx-2(bx59); smo-1(RNAi) arrested as L1 larvae. 
We examined newly hatched larvae to determine if this 
enhanced L1 arrest results from pharyngeal defects. We 
found that both tbx-2(bx59); ubc-9(RNAi) and tbx-2(bx59); 
smo-1(RNAi) double mutants exhibited a synergistic 
increase in the frequency of animals with a severe anterior 
pharyngeal defect compared to the single mutants (table 1; 
Fig. 4). together, these results strongly suggest that 
SUMOylation is necessary for tBX-2 function for anterior 
pharyngeal development.
tBX-2 and SUMOylation are required for repression  
of D2096.6 gene expression
to identify genes downstream of tBX-2, we used microar-
rays to compare mRNa levels in populations of wild-type 
and tbx-2(bx59) embryos grown at 25 °C. We found 1,276 
protein coding genes that are differentially expressed in tbx-
2(bx59) (Bh corrected p ≤ 0.05) (Supplementary table 2). 
a total of 1,030 of these genes (80.7 %) are upregulated 
in tbxc-2(bx59), consistent with our hypothesis that tBX-2 
functions as a transcriptional repressor.
We focused on the gene D2096.6, which had previously 
been shown to be specifically expressed in the pharyngeal 
muscles, marginal cells, and epithelial cells under control 
of the Foxa-family transcription factor Pha-4 [37, 38]. We 
observed an approximately 1.8-fold increase in D2096.6 
expression in tbx-2(bx59) mutants in our microarray (Bh 
corrected p = 0.03). While several candidate t-box bind-
ing sites are located upstream of D2096.6, our preliminary 
characterization of this promoter suggests it is indirectly 
regulated by tBX-2.
to determine how tBX-2 regulates D2096.6 expres-
sion, we compared expression of a D2096.6::gfp reporter 
in wild-type and tbx-2 mutants. Consistent with previous 
studies [37], we observed that a D2096.6::gfp reporter was 
expressed in wild-type embryos specifically in the phar-
ynx at beginning approximately at the bean stage when the 
pharyngeal primordium forms. expression was typically 
observed in one to two cells in the pharynx in one and one-
half fold embryos (Fig. 5), and no expression was observed 
outside the pharynx. the number of GFP-expressing cells 
increased and animals hatched as L1s with GFP expression 
in pharyngeal muscles, marginal cells, and epithelial cells 
(Fig. 5d). In comparison, in tbx-2(bx59) and tbx-2(ok529) 
embryos D2096.6::gfp was expressed in more cells in the 
pharynx, and expression was observed in many cells out-
side the pharynx, including body wall muscles and hypo-
dermal cells (Fig. 5b, c; table 2). ectopic D2096.6::gfp 
expression continued into the L1 larval stage where it was 
observed in bodywall muscle, hypodermal, and gut cells 
(Fig. 5e, f). these results indicate tBX-2 is an upstream 
regulator that represses D2096.6 expression both tempo-
rally and spatially.
to ask if SUMOylation is necessary for tBX-2 function, 
we examined D2096.6 expression in animals where activ-
ity of UBC-9 was reduced using feeding-RNai. the most 
severely affected ubc-9(RNAi) animals have a highly disor-
ganized morphology that makes it difficult to identify spe-
cific tissues [20]. therefore we characterized D2096.6::gfp 
expression in older embryos that had undergone morpho-
genesis and the surviving L1 larvae. ubc-9(RNAi) resulted 
in D2096.6::gfp expression in posterior body wall mus-
cles in embryos in a pattern similar to that which we 
Table 1  Reduction of 
SUMOylation enhances tbx-
2(bx59) embryonic lethality  
and pharyngeal defects
a
 L4 animals raised at 16 °C 
were shifted to 25 °C, and 
defects were scored in the F1 
progeny
Genotypea % embryonic  
arrest (n)
Pharyngeal phenotypes in hatched L1s (percentage of total 
hatched animals)
Severe tbx-2  
pharynx





tbx-2(bx59) 7 (120) 19 56 25 54
ubc-9(RNAi) 19 (186) 7 6 87 69
tbx-2(bx59);  
ubc-9(RNAi)
78 (200) 70 30 0 47
smo-1(RNAi) 65 (347) 22 39 39 49
tbx-2(bx59);  
smo-1(RNAi)
75 (359) 69 26 5 64
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have observed in tbx-2(bx59) and tbx-2(ok529) embryos 
(Fig. 6a, b). In larvae, we observed expression in body 
wall muscles and hypodermal cells in the posterior of the 
worm similar to the expression pattern we see in tbx-2 
mutants (Fig. 6 c, d). thus, SUMO-dependent mechanisms 
repress D2096.6::gfp expression and the similarities in 
the pattern of ectopic expression in ubc-9(RNAi) and tbx-
2 mutants strongly suggests tBX-2 function depends on 
SUMOylation.
Mammalian tbx2 subfamily members can be SUMOylated
to determine if SUMOylation is a conserved mechanism 
regulating t-box factor activity, we asked if mammalian 
orthologs of tBX-2 could be SUMOylated. human tBX2 
or mouse tbx3 tagged with poly-histidine and V5 were 
co-expressed in COS-1 cells with or without ha:SUMO-1 
Fig. 5  D2096.6::gfp is ectopically expressed in tbx-2 mutants. Fluo-
rescence (left) and DIC (right) micrographs of 1.5-fold stage embryos 
(a–c) and L1 larvae (d–f) expressing D2096.6::gfp. a tbx-2(+); 
cuEx553[D2096.6::gfp] embryo containing a single GFP-expressing 
pharyngeal nucleus (arrowhead) and auto-fluorescent gut granules 
(g). b, c tbx-2(bx59); cuEx553 and tbx-2(ok529); cuEx553 embryos 
exhibiting widespread D2096.6::gfp expression outside the pharynx. 
d tbx-2(+); cuEx553 L1 with GFP expression in pharyngeal nuclei. 
e, f tbx-2(bx59); cuEx553 and tbx-2(ok529); cuEx553 L1 larvae. 
Representative bodywall muscle and hypodermal nuclei ectopically 
expressing D2096.6::gfp are marked (bars)
Fig. 6  D2096.6::gfp is ectopically expressed in ubc-9(RNAi) ani-
mals. Fluorescence (left) and DIC (right) micrographs of a tbx-
2(bx59); cuEx553 embryo (a) and a ubc-9(RNAi); cuEx553 embryo 
(b), and L1 larva (c, d) expressing D2096.6::gfp in bodywall muscle 
and hypodermal nuclei (bars). the white bracket indicates the partial 
pharynx in c
Table 2  ectopic expression of D2096.6::gfp
a
 L4 animals raised at 16 °C were shifted to 25 °C, and defects were 
scored in the F1 progeny
b
 Progeny segregating from tbx-2(ok529)/dpy-17(e164) unc-32(e189) 
hermaphrodites were scored. twenty-five % of these progeny are 
expected to be tbx-2(ok529) homozygotes
Genotype % animals with ectopic D2096.6::gfp 
expression (n)
cuEx553[D2096.6::gfp] 5 (136)
tbx-2(bx59); cuEx553a 71 (55)
tbx-2(ok529); cuEx553b 20 (35)
ubc-9(RNAi); cuEx553 75 (48)
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and pulled down using Ni2+-beads under denaturing con-
ditions similarly to C. elegans tBX-2. When co-expressed 
with SUMO-1, both tBX2 and tbx3 formed two more 
slowly migrating SUMOylated bands (Fig. 7). this data 
indicates that other tbx2-subfamily members can be 
SUMOylated, and we hypothesize that SUMOylation may 
be a common regulatory method of t-box factor activity.
Discussion
here we show that C. elegans tBX-2 and its mamma-
lian orthologs human tBX2 and mouse tbx3 can be 
SUMOylated, and that tBX-2 SUMOylation depends 
on two SUMO consensus sites that mediate interaction 
with the e2 SUMO conjugating enzyme UBC-9. We fur-
ther demonstrate that C. elegans tBX-2 can function as 
a transcriptional repressor when fused to a heterologous 
DNa-binding domain; however, mutations that eliminate 
SUMOylation do not affect this repressor activity. Finally, 
we provide genetic evidence that SUMOylation is required 
for tBX-2 function in vivo by showing that reduction of 
SUMOylation enhances the phenotype of a hypomorphic 
tbx-2 mutant and phenocopies the loss of tbx-2 on expres-
sion of one gene that is downstream of tBX-2.
two tBX-2 SUMO consensus sites interact with UBC-9 
and mediate SUMOylation
tBX-2 contains two predicted high-scoring SUMO con-
sensus sites. VKKe located near the C-terminus and LKIe 
located within the t-box DNa-binding domain. each of 
theses sequences interacts with the e2 SUMO-conjugating 
enzyme UBC-9 in yeast two-hybrid assays, and they are the 
only sites that can mediate this interaction.
Our data strongly suggests that both of these sites are 
SUMOylated. We observed multiple SUMOylated forms 
of tBX-2 in COS-1 cells, and mutations affecting either 
SUMO site reduce the amount of SUMOylated tBX-2. 
however, there are differences in how specific mutations 
in these sites affect tBX-2 SUMOylation. For VKKe, 
mutation of the acceptor lysine (K400R) results in a more 
severe reduction in SUMOylation than mutating this site 
completely to alanines. In comparison, mutating the LKIe 
site to alanines results in a large decrease in SUMOylation 
whereas mutation of the acceptor lysine (K231R) has a 
moderate affect and preferentially affects the more slowly 
migrating SUMOylated forms of tBX-2. Mutations affect-
ing only the acceptor lysine likely retain interaction with 
UBC-9 (Sampson et al. 2001), whereas mutations convert-
ing the SUMO site to alanines eliminate UBC-9 binding. 
this difference likely underlies the different effects we 
observed on tBX-2 SUMOylation when these sites are 
mutated.
t-boxes have a highly conserved structure when bound 
to DNa [39–42], and tBX-2 LKIe is located within the 
α3 helix that spans the DNa backbone. While SUMOyla-
tion can occur in α helices [43, 44], this is an unusual 2˚ 
structure for UBC-9 interaction and SUMOylation, as 
UBC-9 has been shown to bind SUMO consensus sites in 
extended loops [18, 45]. however, recent evidence indi-
cates that some t-boxes have significant structural flex-
ibility that might allow SUMOylation at LKIe. the tbx20 
t-box exists as a molten globule with an unstable tertiary 
structure allowing flexibility between 2° structural domains 
[46]. Likewise in tBX5, the 310-helix located just C termi-
nal to the α3 helix is unstructured in the absence of DNa 
[42]. While the α3 helix remains structured when tBX5 is 
not bound to DNa, the LKIe site would be more accessible 
to bind UBC-9.
LKIe was also investigated as a potential SUMOylation 
site in the human t-box factor tBX22 [47]. Interestingly, 
mutation of this site eliminated tBX22 SUMOylation, 
however, this is believed to result indirectly from possi-
ble effects on DNa binding as was observed with several 
DNa-binding defective mutants. Biochemical analyses of 
SUMOylated t-box factors is necessary to explicitly deter-
mine if this site is SUMOylated in different proteins.
tbx-2 genetically interacts with ubc-9 and smo-1
tbx-2(bx59); ubc-9(RNAi) and tbx-2(bx59); smo-1(RNAi) 
animals exhibit penetrant embryonic arrest and enhanced 
pharyngeal defects, indicating that reduced SUMOyla-
tion affects tBX-2 activity in vivo. In particular, the 
Fig. 7  SUMOylation of mammalian tbx2 subfamily members 
Western blots of Ni–Nta pulled-down human tBX2/V5/hIS and 
mouse tbx3/V5/hIS probed to detect tBX2 and tbx3 (bottom) or 
SUMO-1 (top). Combinations of proteins expressed in COS-1 cells 
are indicated (grey boxes). SUMOylated forms of tBX2 and tbx3 
are marked with arrowheads, and MW weight markers are indicated 
(kDa). a cross-reacting background band was detected in all lanes 
using anti-ha
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enhanced pharyngeal phenotype of these animals resem-
bles that of tbx-2 null mutants, strongly suggesting that 
tbx-2 and SUMOylation function in the same pathway to 
specify pharyngeal muscle fate [48]. these observations 
are consistent with the hypothesis that tBX-2 function is 
SUMO-dependent.
In comparison, we do not know why enhanced embry-
onic lethality was observed in tbx-2(bx59); ubc-9(RNAi) 
and tbx-2(bx59); smo-1(RNAi) animals. Neither tbx-2 null 
mutants nor tbx-2(RNAi) animals exhibit embryonic lethal-
ity [20], indicating lethality does not result from loss of 
zygotic tbx-2(bx59) activity. One possibility is that tbx-
2(bx59) may have a partial gain-of-function character, 
and reducing SUMOylation deregulates this activity. tbx-
2(bx59) mutates a conserved histidine residue within the 
dimerization domain of the t-box to a tyrosine (h145Y; 
accession CCD69847), and mutations affecting this domain 
in human tBX1 result in gain-of-function associated with 
some cases of DiGeorge and velocardiofacial syndromes 
[49]. alternatively, decreased SUMOylation of a paren-
tally provided, RNai-resistant protein or mRNa tbx-2 gene 
product might be required for viability. Finally, decreased 
SUMOylation may affect SUMO-dependent activity of 
both tBX-2 and another factor with a partially redundant 
activity required for embryogenesis.
how might SUMOylation affect tBX-2 activity?
SUMOylation of transcription factors is usually associated 
with transcriptional repression, and it can promote recruit-
ment of chromatin remodeling and histone modifying com-
plexes [12, 50]. Indeed, SUMOylation of the C. elegans 
ets-domain factor LIN-1 leads to interaction with MeP-1 
and the NuRD chromatin repressor complex [51]. however, 
our results argue that SUMOylation affects tBX-2 function 
by a different mechanism. Unlike LIN-1, repressor activ-
ity of tBX-2:GaL4 fusion protein in mammalian cells is 
independent of SUMOylation, and in extensive yeast two-
hybrid screens tBX-2 has not been observed to interact 
with MeP-1 [20].
SUMOylation at the LKIe site in the t-box would likely 
affect the ability of tBX-2 to bind sites in the genome and 
to interact with other factors binding tBX-2 regulated pro-
moters. If this is the case, our assays for tBX-2:GaL4 
repressor activity would be insensitive to SUMOylation, 
since they depend on a heterologous DNa-binding domain 
targeting a synthetic promoter. Indeed, SUMOylation has 
been shown to affect DNa-binding activity of specific tran-
scription factors [52–54].
It is difficult to predict how SUMOylation at the VKKe 
site would affect tBX-2 activity. t-box proteins are 
poorly conserved outside of the DNa-binding domain, 
and the function of the tBX-2 C-terminus is unknown. 
Interestingly, our preliminary results indicate VKKe is 
located near an interaction site for the Groucho-family co-
repressor UNC-37 (t. Crum and P. Okkema, unpublished). 
SUMOylation can regulate interaction with Groucho-fam-
ily proteins [55, 56], and we hypothesize SUMOylation at 
VKKe has a similar function. Groucho-interaction motifs 
are enriched in t-box factors from C. elegans, Drosoph-
ila, and humans [57], and several t-box factors have been 
shown to interact with Groucho-family proteins [58–61]. 
SUMOylation may be a common mechanism for regulating 
t-box factor interaction with Groucho.
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